Literature DB >> 24180681

A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex.

David H Harter1, Luigi Bassani, Shaun D Rodgers, Jonathan Roth, Orrin Devinsky, Chad Carlson, Jeffery H Wisoff, Howard L Weiner.   

Abstract

OBJECT: Subependymal giant cell astrocytomas (SEGAs) are benign tumors, most commonly associated with tuberous sclerosis complex (TSC). The vast majority of these tumors arise from the lateral ependymal surface adjacent to the foramen of Monro, therefore potentially encroaching on one or both foramina, and resulting in obstructive hydrocephalus that necessitates surgical decompression. The indications for surgery, intraoperative considerations, and evolution of the authors' management paradigm are presented.
METHODS: Patients with TSC who underwent craniotomy for SEGA resection at New York University Langone Medical Center between January 1997 and March 2011 were identified. Preoperative imaging, clinical characteristics, management decisions, operative procedures, and outcomes were reviewed.
RESULTS: Eighteen patients with TSC underwent 22 primary tumor resections for SEGAs. The indication for surgery was meaningful radiographic tumor progression in 16 of 21 cases. The average age at the time of operation was 10.3 years. Average follow-up duration was 52 months (range 12-124 months). The operative approach was intrahemispheric-transcallosal in 16 cases, transcortical-transventricular in 5, and neuroendoscopic in 1. Nine tumors were on the right, 9 on the left, and 3 were bilateral. Gross-total resection was documented in 16 of 22 cases in our series, with radical subtotal resection achieved in 4 cases, and subtotal resection (STR) in 2 cases. Two patients had undergone ventriculoperitoneal shunt placement preoperatively and 7 patients required shunt placement after surgery for moderate to severe ventriculomegaly. Two patients experienced tumor progression requiring reoperation; both of these patients had initially undergone STR.
CONCLUSIONS: The authors present their management strategy for TSC patients with SEGAs. Select patients underwent microsurgical resection of SEGAs with acceptable morbidity. Gross-total resection or radical STR was achieved in 90.9% of our series (20 of 22 primary tumor resections), with no recurrences in this group. Approximately half of our patient series required CSF diversionary procedures. There were no instances of permanent neurological morbidity associated with surgery.

Entities:  

Mesh:

Year:  2013        PMID: 24180681     DOI: 10.3171/2013.9.PEDS13193

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  9 in total

Review 1.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein levels, CSF clotting, and communicating hydrocephalus: a comprehensive review.

Authors:  Yosef Laviv; Burkhard S Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-07       Impact factor: 3.042

2.  Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.

Authors:  Flavio Giordano; Carla Moscheo; Matteo Lenge; Roberto Biagiotti; Francesco Mari; Iacopo Sardi; Anna Maria Buccoliero; Lorenzo Mongardi; Eleonora Aronica; Renzo Guerrini; Lorenzo Genitori
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

3.  Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.

Authors:  Joel S Katz; Hyman Frankel; Tracy Ma; David Zagzag; Benjamin Liechty; Bruria Ben Zeev; Michal Tzadok; Orrin Devinsky; Howard L Weiner; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2017-01-10       Impact factor: 1.475

4.  Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex.

Authors:  Martine Fohlen; Sarah Ferrand-Sorbets; Olivier Delalande; Georg Dorfmüller
Journal:  Childs Nerv Syst       Date:  2018-05-15       Impact factor: 1.475

5.  Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis.

Authors:  Paolo Frassanito; Carolina Noya; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-09-25       Impact factor: 1.475

6.  Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.

Authors:  Kyoichi Tomoto; Ayataka Fujimoto; Chikanori Inenaga; Tohru Okanishi; Shin Imai; Masaaki Ogai; Akiko Fukunaga; Hidenori Nakamura; Keishiro Sato; Akira Obana; Takayuki Masui; Yoshifumi Arai; Hideo Enoki
Journal:  BMC Neurol       Date:  2021-03-31       Impact factor: 2.474

Review 7.  MRI-based diagnosis and treatment of pediatric brain tumors: is tissue sample always needed?

Authors:  Jehuda Soleman; Rina Dvir; Liat Ben-Sira; Michal Yalon; Frederick Boop; Shlomi Constantini; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2021-04-05       Impact factor: 1.475

8.  EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Authors:  Andras Fogarasi; Liesbeth De Waele; Gabriella Bartalini; Sergiusz Jozwiak; Nicola Laforgia; Helene Verhelst; Borivoj Petrak; Jean-Michel Pedespan; Olaf Witt; Ramon Castellana; Stefania Crippa; Gabriella Gislimberti; Zsuzsanna Gyorsok
Journal:  BMC Neurol       Date:  2016-08-08       Impact factor: 2.474

9.  Subependymal Giant Cell Astrocytoma: Associated Hyperproteinorrhachia Causing Shunt Failures and Nonobstructive Hydrocephalus - Report of Successful Treatment with Long-term Follow-up.

Authors:  Ekkehard Kasper; Yosef Laviv; Mohammed-Adeeb E Sebai; Ning Lin; William Butler
Journal:  Asian J Neurosurg       Date:  2017 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.